
De studie includeerde 2585 volwassen patiënten (48% in Frankrijk, 34% in Duitsland, 19% in Canada) met stadium IIIB of IV NSCLC die nivolumab kregen na tenminste één eerder lijn systemische therapie. De mediane overall survival was 11,3 maanden (95%-bti 10,5-12,2) zonder significante verschillen tussen de drie landen. Eén-jaars OS was 49% en twee-jaars OS was 28%. Factoren die in univariate analyse geassocieerd waren met significant kortere OS waren EGFR-mutaties in squameuze ziekte en lever- of botmetastase, terwijl PD-L1 expressie en ECOG performance status 0 of 1 geassocieerd waren met significant langere OS.
De onderzoekers concluderen dat de overleving die met nivolumab wordt gezien in real-world aNSCLC-patiënten niet sterk afwijkt van wat is gezien in fase 3-studies.
1.Debieuvre D, Juergens RA, Asselain B et al. Two-year survival with nivolumab in previously treated advanced non-small cell lung cancer: a real-world pooled analysis of patients from France, Germany and Canada. Lung Cancer 2021.04.22
Summary: Analysis of data from real-world patients with previously treated aNSCLC in France, Germany, and Canada found that OS rates with nivolumab were similar to what has been seen in phase 3 studies.